Skip to content
Clinical Trials – home

Academisch Ziekenhuis Maastricht

Verified siteinfo

The Netherlands P. O. Box 5800, 6202 AZ Maastricht, The Netherlands

  • 2 trials recruiting
  • Acute myeloid leukaemia · Aortic valve stenosis · Bladder cancer
  • Adult patients

About Specializations

Academisch Ziekenhuis Maastricht in Maastricht, The Netherlands specialises in clinical trials of conditions such as Acute myeloid leukaemia, Aortic valve stenosis, Bladder cancer, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of cancer. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies and personalized medicine.

  • Non-Small Cell Lung Cancer
  • Gastroenteropancreatic Neuroendocrine Tumors
  • Endometrial Cancer
  • Cervical Cancer
  • Prostate Cancer

By integrating clinical trials with translational research, the center is advancing the understanding of cancer biology and developing new therapeutic strategies.

Cardiology

Specializing in cardiology, the center is dedicated to pioneering research in cardiovascular diseases. The focus is on developing novel interventions and improving existing treatments to enhance patient care and outcomes.

  • Acute Heart Attack
  • Aortic Stenosis
  • Genetic Dilated Cardiomyopathy

The center's research efforts are aimed at understanding the underlying mechanisms of heart diseases and translating these findings into effective clinical applications.

Hematology

The center is a leader in hematology research, focusing on blood disorders and hematologic malignancies. The research conducted here is instrumental in developing new therapies and improving patient management strategies.

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma

Through collaborative efforts and clinical trials, the center is advancing the treatment landscape for hematologic conditions, offering hope to patients worldwide.

Nephrology

In the field of nephrology, the center is committed to advancing research on kidney diseases. The focus is on innovative treatments and improving the quality of life for patients with renal conditions.

  • Acute Kidney Injury
  • Lupus Nephritis
  • IgA Nephropathy

The center's research initiatives are aimed at understanding the pathophysiology of kidney diseases and developing targeted therapies to address these challenges.

Immunology

Focusing on immunology, the center is dedicated to exploring the immune system's role in health and disease. The research conducted here is pivotal in developing new immunotherapies and enhancing existing treatment protocols.

  • Primary Immunodeficiency Diseases
  • Psoriatic Arthritis
  • Autoimmune Disorders

By leveraging cutting-edge technologies and collaborative research, the center is making significant strides in understanding and treating immune-related conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
P. O. Box 58006202 AZ MaastrichtThe Netherlands
Recruiting now
2 trials
Conditions studied
16
Partner status
Verified site

More sites in MaastrichtThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:St Antonius Hospital

Corneal transplant+2

Recruiting

Study on Dexamethasone and Fluorometholone for Patients Undergoing Corneal Transplantation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Academisch Ziekenhuis Maastricht

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasm

Not recruiting

Study of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effect of Empagliflozin, Acetylcholine Chloride, Insulin Aspart, and Sodium Nitroprusside Dihydrate on Heart Failure with Preserved Ejection Fraction Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Academisch Ziekenhuis Maastricht

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.